Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022

Latest Articles

  • Should everyone with a recent myocardial infarction receive a beta-blocker and an ACE inhibitor?
    You have access
    Should everyone with a recent myocardial infarction receive a beta-blocker and an ACE inhibitor?
    John C. Hostetter, MD and Sasan Ghaffari, MD
    Cleveland Clinic Journal of Medicine January 2003, 70 (1) 46-48;

    Yes, except for those with the standard contraindications to these drugs.

  • You have access
    Thyrotoxicosis and the cardiovascular system: Subtle but serious effects
    Marco Roffi, MD, Fabio Cattaneo, MD and Eric J. Topol, MD
    Cleveland Clinic Journal of Medicine January 2003, 70 (1) 57-63;

    One should suspect thyrotoxicosis in patients with palpitations, tachycardia, exercise intolerance, or dyspnea on exertion.

  • Migraine treatments– what you can expect
    You have access
    Migraine treatments– what you can expect
    Cleveland Clinic Journal of Medicine January 2003, 70 (1) 30;
  • You have access
    Cyber-CME and the Journal’s computer-literate readers
    John D. Clough, MD
    Cleveland Clinic Journal of Medicine January 2003, 70 (1) 7;

    Congratulations to you, our readers, on your adaptability and computer literacy.

  • You have access
    A 62-year-old man with sudden onset of orthopnea and left shoulder weakness and pain
    William C. Cook, DO and Jeffrey Chapman, MD
    Cleveland Clinic Journal of Medicine January 2003, 70 (1) 66-69;

    What is the cause of this patient’s symptoms? A self-test.

  • You have access
    The metabolic syndrome: A tug-of-war with no winner
    Daniel J. Brotman, MD and John P. Girod, DO
    Cleveland Clinic Journal of Medicine December 2002, 69 (12) 990-994;

    Even before beta cells fail, the deadly quartet is quietly rehearsing.

  • You have access
    The HIP trial
    Chad L. Deal, MD
    Cleveland Clinic Journal of Medicine December 2002, 69 (12) 964-976;

    Patients should be selected for bisphosphonate therapy on the basis of low bone density, not age.

  • You have access
    Index to Volume 69
    Cleveland Clinic Journal of Medicine December 2002, 69 (12) 1002-1006;
  • You have access
    HIV update 2002
    Wendy Armstrong, MD, Leonard Calabrese, DO and Alan Taege, MD
    Cleveland Clinic Journal of Medicine December 2002, 69 (12) 995-999;

    “Treat early, treat hard” is changing to “treat a little later, treat hard.”

  • You have access
    Update on the diagnosis and treatment of human papillomavirus infection
    Kristine M. Zanotti, MD and Jerome Belinson, MD
    Cleveland Clinic Journal of Medicine December 2002, 69 (12) 948-961;

    Genotyping can distinguish viral subtypes that pose a high risk for cancer, but current therapies do not reliably eradicate the virus, and warts and neoplasia often recur after treatment.

Pages

  • Previous
  • Next
  • 1
  • …
  • 373
  • 374
  • 375
  • 376
  • 377
  • 378
  • 379
  • 380
  • 381
  • …
  • 799

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2026 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire